Rory, thanks for being the most transparant CEO i've ever

New Post Public Reply Private Reply Replies (0) Message Board
jamiejaytrader
386
Rory, thanks for being the most transparant CEO i've ever witnessed in my life!
I truely admire your communication and dedication to us co-owners!
Many many MANY thanks!

To all the true longs out there that are helping out newbies and others, a big thank you also for your outstanding DD and sharing!

I'm a long who has been adding along the way since this was in the 50 cent range and i try to keep adding to my position with every big dip when i can.

My shares are locked up and not worried about short term swings.
Done enough DD to see where this stock is heading and i am comfortably enjoying life while i'm making money sleeping

I do have a question for the board though:

When we get the 2 independent directors and we are comfortably say above $7 (end of may imho, with nrs reported officially) maybe even higher, who knows.

In what time frame could we be looking at for uplisting?
In the past i always thought it takes 9 months minimal but i also recall reading (this was a long time ago) that it could be achieved in like a few weeks. Does anyone know for sure?

I'm in the mindset right now that it could happen quicker then i'm thinking.
I see the minimum requirement of $4 easily being achieved by end of may (probably a lot sooner with Oracle and Marketo's PR's coming this week).
I know Rory is busy with getting those 2 independent directors already....

Just wanted to know if someone on the board knows what would be a minimum time frame to uplist once we get the 2 independent directors hired and we have the minimum of $4 required for uplisting.

Thanks!
Jamie

TON Strategy Co. (TONX) Stock Research Links

TONX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

USDA Under Scrutiny as ASPCA Reports on Puppy Mill Violations

Updated Category News Views 322

ASPCA's Shocking Report on Puppy Mill Violations In a recent analysis by the ASPCA, alarming statistics have surfaced regarding animal welfare violations at USDA-licensed commercial dog breeding facilities. The findings reveal that in a given year, substantial breaches of care standards were documented, yet no actions were taken to ensure the safety of the animals....

Continue Reading
PowerReviews Unveils Partner Program to Amplify UGC Value

Updated Category News Views 1653

PowerReviews Launches Comprehensive Partner Program PowerReviews, a reputable name backed by 1WorldSync, has initiated an exciting Partner Program aimed at revolutionizing the way user-generated content (UGC) is leveraged. This initiative is designed to not only boost productivity but also facilitate enhanced revenue opportunities for partners who promote its advanced...

Continue Reading
Turnspire Capital Partners Expands Portfolio with GHP Group

Updated Category News Views 81

Turnspire Capital Partners pulled the trigger on acquiring GHP Group back in 2024, a move that sent shockwaves through the consumer product landscape. This was no random buy; GHP's got its fingers in the pie of outdoor living products—think patio heaters and grills—all under reputable brands like Dyna-Glo and Pleasant Hearth. GHP Group: A Heavyweight Player in Outdoor...

Continue Reading
MPI Corporation Launches Groundbreaking 250 GHz Probe System

Updated Category News Views 187

Enhancing Precision in Semiconductor Testing In the fast-evolving world of semiconductor technology, precision and performance are critical. MPI Corporation has once again demonstrated its innovative spirit by unveiling a revolutionary 250 GHz broadband test solution. This state-of-the-art system combines the power of the TITAN™ Probes and MPI's extensive expertise in...

Continue Reading
Passage Bio's Gene Therapy Strategy: Hope for Dementia Treatments

Updated Category News Views 76

Promising Advances in Gene Therapy Recently, Passage Bio, Inc. (NASDAQ: PASG), a pioneering company in genetic medicine, showcased groundbreaking preclinical and interim clinical results for its gene therapy product, PBFT02. This was presented at a major congress focused on gene and cell therapy. Designed specifically to target frontotemporal dementia associated with GRN...

Continue Reading